Clareo Health | Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Roxall Medicina España S.A
Age
5–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patients aged between 5 and 60 years who present rhinitis or allergic rhinoconjunctivitis caused by IgE-mediated sensitization to more than one allergen source with or without mild / moderate asthma.
2. Patients eligible for immunotherapy treatment with Allergovac Poliplus according to investigator criteria.
3. Patients must provide written informed consent. It is the case of children , the legal representative or tutor of the child must sign the inform consent form.
You may not be if
1. Patients that according to the investigator criteria may present difficulties for understanding the patient information sheet, completing the questionnaires and self-administered scales.
2. Patients that according to the investigator may present difficulties to complete the patient diary.
3. Patients who are participating in another clinical trial or observational study.
